The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice

Vaccine

Volumn 14, Issue 10, 1996, Pages 971-976

  Harris, S J ^a   Woodrow, S A ^a   Gearing, A J H ^a   Adams, S E ^a   Kingsman, A J ^b   Layton, G T ^a  

^a British Biotech Pharmaceuticals Ltd   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adjuvants; Cytotoxic T lymphocyte; HIV 1 V3; Virus like particles

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; CHEMIVAX; EDETIC ACID; FREUND ADJUVANT; GALACTOSAMINE; GLYCOPROTEIN GP 120; INULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MURAMYL DIPEPTIDE; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS PARTICLE;

EID: 0030198395     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(96)00010-2     Document Type: Article

References (28)

1. 1 Cohen, J. AIDS research shifts to immunity. Science 1992, 257, 152-154
2. + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin. Immunol. Immunopathol. 1993, 69, 106-116
3. 3 Schild, H., Deres, K., Weismüller, K-H., Jung, G. and Rammensee H.G. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur. J. Immunol. 1991, 121, 2649-2654
4. 4 Raychaudhuri, S., Tonks, M., Carbone, F., Ryskamp, T., Morrow, W.J.W. and Hanna, N. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc. Natl Acad. Sci. USA 1992, 89, 8308-8312
5. + cytotoxic T cells. Vaccine 1994, 12, 73-80
6. + cytotoxic T cells by immunisation with purified HIV-1 envelope protein in ISCOMs. Nature 1990, 344, 873-875
7. 7 Wu, J., Gardner, H., Murphy, C.I. et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol. 1992, 148, 1519-1525
8. 8 Harding, C.V. and Song, R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 1994, 153, 4925-4933
9. 9 Schirmbeck, R., Melber, K., Kuhröber, A., Janowicz A. and Reimann, J. Immunisation with soluble Hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. J. Immunol. 1994, 152, 1110-1119
10. 10 Layton, G.T., Harris, S.J., Gearing, A.J.H. et al. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J. Immunol. 1993, 151, 1097-1107
11. 11 Griffiths, J.C., Berrie, E.L., Holdsworth, L.N. et al. Induction of high-titre neutralizing antibodies using hybrid Human Immunodeficiency Virus V3:Ty-VLPs in a clinically relevant adjuvant. J. Virol. 1991, 65, 450-456
12. 12 Harris, S.J., Gearing, A.J.H., Layton, G.T., Adams, S.E. and Kingsman, A.J. Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunisation with V3:Ty virus-like particles. Immunology 1992, 77, 315-321
13. 13 Amador, R., Moreno, A., Valero, V. et al. The first field trials of the chemically synthetized malaria vaccine Spf66: safety, immunogenicity and protectivity. Vaccine 1992, 10, 179-184
14. 14 Coleman, P.C., Shaw, F.E., Serovich, J., Hadler, S.C. and Margolis, H.S. Intradermal hepatitis B vaccination in a large hospital employee population. Vaccine 1991, 9, 723-727
15. 15 Mitchell, M.S., Kan-Mitchell, J., Kempf, R.A., Harel, W., Shau, H. and Lind, S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988, 48, 5883-5893
16. H2 pathway in interferon γ-deficient mice infected with Lieshmania major. J. Exp. Med. 1994, 179, 1367-1371
17. H1 development of CD4+ T cells from aβ TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-γ-dependent. Int. Immunol. 1993, 5, 1119-1128
18. 18 Zhou, F. and Huang, L. Monophosphoryl lipid A enhanced specific CTL induction by protein antigen entrapped in liposomes. Vaccine 1993, 11, 1139-1144
19. 19 Zhou, X., Berg, L., Motal, U.M.A. and Jondal, M. In vivo induction of virus-specific CTL by immunisation with 9-mer synthetic peptides. J. Immunol. Meth. 1992, 153, 193-200
20. 20 Bryars, N.E. and Allison, A.C. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine 1987, 5, 223-228
21. 21 Bomford, R., Stapleton, M., Winsor, S., McKnight, A. and Andronova, T. The control of the antibody isotype response to recombinant Human Immunodeficiency Virus gp120 antigen by adjuvants. AIDS Res. Human Retrovir. 1992, 10, 1765-1771
22. 22 Pfeifer, J.D., Wick, M.J., Roberts, R.L., Findlay, K., Normark, S.J. and Harding, C.V. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993, 361, 359-361
23. 23 Cooper, P.D. and Steele, E.J. The adjuvanticity of gamma inulin. Immunol. Cell Biol. 1988, 66, 345-352
24. 24 Doel, H.S., Palmer, D.G., Dunsmore, T. and Carnegie, P.R. The influence of gamma inulin and Algamulin on the immune response in sheep to a recombinant antigen of Taenia ovis. Vaccine 1995, 13, 429-433
25. 25 Cooper, P.D., McComb, C. and Steele, E.J. The adjuvanticity of Algamulin, a new vaccine adjuvant. Vaccine 1991, 9, 408-433
26. H2 responses. Immunol. Today 1991, 12, A49-A53
27. 27 Dillon, S.B., Demuth, S.G., Schneider, M.A. et al. Induction of protective MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant. Vaccine 1992, 10, 309-318
28. 28 Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B. and Rock, K.L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA 1993, 90, 4942-4946